
Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...



